CNBC's "Options Action" is your front row seat to the fastest-growing corner of the markets. With guidance from industry experts, exclusive data, and the latest news, Options Action explains complex ...
Following in the footsteps of the other review programs at the US Food and Drug Administration's (FDA) Office of Pharmaceutical Science, the Office of Biotechnology Products (OBP) is currently in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results